BamSEC and AlphaSense Join Forces
Learn More

Nuvation Bio Inc. – Material Contracts

NYSE: NUVB    
Share price (9/24/26): $5.73    
Market cap (9/24/26): $2.012 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 3 pages Non-Employee Director Compensation Policy of Nuvation Bio Inc
12/34/56
EX-10.1
from 10-Q 72 pages Amended and Restated License Agreement Between Daiichi Sankyo Company, Limited and Nuvation Bio Inc
12/34/56
EX-10.2
from 8-K 29 pages [Dealer Name and Address] To: Nuvation Bio Inc. 1500 Broadway, Suite 1401 New York, New York 10036 From: [Dealer] Re: [Base][additional] Capped Call Transaction Date: [ ], 2026 Dear Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 109 pages First Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.6
from 10-Q 12 pages Material contract
12/34/56
EX-10.5
from 10-Q 59 pages June 28, 2019 Gary Hattersley, PH.D. 22 Brandymeade Circle Stowe, Ma 01775 Re: Offer Letter for Chief Scientific Officer Dear Gary
12/34/56
EX-10.4
from 10-Q 12 pages 30 September 2024 Philippe Sauvage 45 Mount Vernon Street Cambridge, Ma 02140 Re: Offer Letter
12/34/56
EX-10.3
from 10-Q 9 pages April 30, 2022 Dongfang Liu, MD, Phd 12925 Northeast 100th Lane Kirkland, Wa 98033 Re: Offer Letter for Chief Medical Officer
12/34/56
EX-10.2
from 10-Q 7 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 76 pages License and Collaboration Agreement
12/34/56
EX-10.29
from 10-K 6 pages Amendment 1 to Contract Manufacturing Agreement
12/34/56
EX-10.28
from 10-K 7 pages Amendment 2 to Contract Manufacturing Agreement
12/34/56
EX-10.27
from 10-K 6 pages Amendment 1 to Contract Manufacturing Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Non-Employee Director Compensation Policy of Nuvation Bio Inc
12/34/56
EX-10.4
from 10-Q 38 pages Contract Manufacturing Agreement (Drug Product) by and Between Nuvation Bio Inc. and Asymchem Life Science (Tianjin) Co., Ltd
12/34/56
EX-10.3
from 10-Q 39 pages Contract Manufacturing Agreement (Api) by and Between Nuvation Bio Inc. and Asymchem Laboratories (Tianjin) Co., Ltd
12/34/56
EX-10.1
from 10-Q 24 pages Nuvation Bio Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: January 17, 2021 Approved by the Stockholders: February 9, 2021 Amended by the Compensation Committee: January 21, 2025
12/34/56
EX-10.24
from 10-K 103 pages Revenue Interest Financing Agreement by and Between Nuvation Bio Inc., as the Company, and Sagard Healthcare Partners (Delaware) II LP, as the Investor Dated March 3, 2025
12/34/56
EX-10.3
from 8-K/A 35 pages License and Commercialization Agreement
12/34/56
EX-10.2
from 8-K/A 10 pages Amendment to Collaboration and License Agreement Between Anheart Therapeutics (Hangzhou) Co., Ltd. (葆元生物医药科技（杭州）有限公司 ) and Innovent Biologics (Suzhou) Co., Ltd. (信达生物制药（苏州）有限公司 ) Date November 30, 2022
12/34/56